Total Payments
$75,660
2024 Payments
$41,608
Companies
51
Transactions
770
Medicare Patients
5,750
Medicare Billing
$472,170
Payment Breakdown by Category
Research$43,427 (57.4%)
Food & Beverage$20,800 (27.5%)
Consulting$9,095 (12.0%)
Other$1,391 (1.8%)
Travel$584.85 (0.8%)
Education$361.18 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $43,427 | 21 | 57.4% |
| Food and Beverage | $20,800 | 699 | 27.5% |
| Consulting Fee | $9,095 | 4 | 12.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,391 | 10 | 1.8% |
| Travel and Lodging | $584.85 | 3 | 0.8% |
| Education | $361.18 | 33 | 0.5% |
Payments by Type
Research
$43,427
21 transactions
General
$32,233
749 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $42,447 | 5 | $0 (2024) |
| Novo Nordisk Inc | $13,417 | 100 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,422 | 75 | $0 (2024) |
| Allergan, Inc. | $2,049 | 38 | $0 (2022) |
| Lilly USA, LLC | $1,718 | 67 | $0 (2024) |
| ABBVIE INC. | $1,666 | 73 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,664 | 53 | $0 (2024) |
| Amgen Inc. | $1,367 | 37 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,182 | 36 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,159 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,608 | 76 | Eli Lilly and Company ($40,094) |
| 2023 | $4,896 | 93 | Eli Lilly and Company ($2,353) |
| 2022 | $2,822 | 90 | Allergan, Inc. ($525.80) |
| 2021 | $4,890 | 85 | Novo Nordisk Inc ($2,294) |
| 2020 | $1,308 | 72 | GlaxoSmithKline, LLC. ($233.74) |
| 2019 | $5,355 | 95 | Novo Nordisk Inc ($2,743) |
| 2018 | $11,316 | 130 | Novo Nordisk Inc ($6,924) |
| 2017 | $3,465 | 129 | AstraZeneca Pharmaceuticals LP ($492.12) |
All Payment Transactions
770 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Cardio-renal | ||||||
| 12/09/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $5.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/18/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,474.96 | Research |
| 11/15/2024 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: Endo-Mechanical | ||||||
| 11/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Cardio-renal | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Gastroenterology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Respiratory | ||||||
| 10/29/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: Diabetes | ||||||
| 10/24/2024 | Eli Lilly and Company | — | — | In-kind items and services | $3.36 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 10/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $149.93 | General |
| Category: Cardio-renal | ||||||
| 10/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: PAIN | ||||||
| 10/08/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/01/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $14.73 | General |
| 09/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Cardio-renal | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $38,616.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $9.97 | General |
| Category: RESPIRATORY | ||||||
| 09/11/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Diabetes | ||||||
| 09/11/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $2.39 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2024 | Teleflex LLC | UROLIFT (Device) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: INTERVENTIONAL UROLOGY | ||||||
| 08/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: NEUROSCIENCE | ||||||
| 08/27/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: RESPIRATORY | ||||||
| 08/21/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Durable Pump | ||||||
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Respiratory | ||||||
| 08/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.08 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.84 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $38,616 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $1,626 | 2 |
| A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH | GlaxoSmithKline, LLC. | $980.46 | 16 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $730.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,422 | 2,111 | $188,223 | $115,967 |
| 2022 | 17 | 1,068 | 1,732 | $164,980 | $101,815 |
| 2021 | 24 | 1,745 | 2,601 | $225,541 | $137,129 |
| 2020 | 23 | 1,515 | 2,436 | $305,853 | $117,259 |
Total Patients
5,750
Total Services
8,880
Medicare Billing
$472,170
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 270 | 676 | $65,010 | $39,119 | 60.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 223 | 435 | $56,690 | $35,872 | 63.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 100 | 100 | $18,140 | $12,473 | 68.8% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 124 | 124 | $12,400 | $7,033 | 56.7% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 27 | 35 | $8,750 | $5,361 | 61.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 82 | 86 | $3,010 | $2,564 | 85.2% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 144 | 144 | $2,880 | $2,560 | 88.9% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 126 | 126 | $2,520 | $2,240 | 88.9% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 13 | 13 | $3,250 | $2,074 | 63.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $4,000 | $1,806 | 45.1% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 83 | 87 | $2,610 | $1,757 | 67.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 119 | 125 | $3,740 | $1,293 | 34.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 54 | $1,890 | $456.96 | 24.2% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 12 | 14 | $1,248 | $440.40 | 35.3% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 12 | 12 | $360.00 | $296.64 | 82.4% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 20 | 21 | $735.00 | $286.00 | 38.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 12 | 12 | $720.00 | $246.96 | 34.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 23 | 27 | $270.00 | $88.66 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 270 | 652 | $62,940 | $38,190 | 60.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 220 | 437 | $58,090 | $35,346 | 60.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 44 | 44 | $7,990 | $5,603 | 70.1% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 27 | 30 | $7,700 | $4,655 | 60.5% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 63 | 63 | $6,300 | $4,072 | 64.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 81 | 86 | $3,015 | $2,454 | 81.4% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 14 | 14 | $3,500 | $2,290 | 65.4% |
About Dr. James Beach, D.O
Dr. James Beach, D.O is a Family Medicine healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1053304808.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Beach, D.O has received a total of $75,660 in payments from pharmaceutical and medical device companies, with $41,608 received in 2024. These payments were reported across 770 transactions from 51 companies. The most common payment nature is "" ($43,427).
As a Medicare-enrolled provider, Beach has provided services to 5,750 Medicare beneficiaries, totaling 8,880 services with total Medicare billing of $472,170. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Phoenix, AZ
- Active Since 08/26/2005
- Last Updated 10/29/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1053304808
Products in Payments
- Victoza (Drug) $8,251
- RYBELSUS (Drug) $2,160
- Ozempic (Drug) $1,447
- JARDIANCE (Drug) $980.02
- VRAYLAR (Drug) $840.41
- TRELEGY ELLIPTA (Drug) $839.94
- FARXIGA (Drug) $667.61
- TRULICITY (Drug) $636.62
- MOUNJARO (Drug) $590.36
- Prolia (Biological) $545.95
- Tresiba (Drug) $524.87
- INVOKANA (Drug) $514.58
- QULIPTA (Drug) $425.93
- Kerendia (Drug) $414.70
- ZENPEP (Drug) $373.66
- TOUJEO (Drug) $359.01
- BEVESPI AEROSPHERE (Drug) $292.70
- SYMBICORT (Drug) $263.69
- Repatha (Biological) $262.60
- Aimovig (Biological) $254.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Phoenix
Mitchell Edelstein
Family Medicine — Payments: $815,023
Family Medicine $815,023
Benjamin Heller
Family Medicine — Payments: $76,549
Family Medicine $76,549
Ahmed Agha, M.d., Pharmd, M.D., PHARMD
Family Medicine — Payments: $66,368
Family Medicine $66,368
Valerie Miranda, M.d, M.D
Family Medicine — Payments: $66,025
Family Medicine $66,025
Dr. Gautam Aggarwal, Md, MD
Family Medicine — Payments: $51,628
Family Medicine $51,628
Dr. Donald Mulvaney, M.d, M.D
Family Medicine — Payments: $40,999
Family Medicine $40,999